27 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
UBS Group (UBS) Seeks Wealth Management Growth in the US https://www.zacks.com/stock/news/2242415/ubs-group-ubs-seeks-wealth-management-growth-in-the-us?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2242415 Mar 18, 2024 - UBS Group (UBS) seeks merger and acquisition opportunities in the United States to expand its wealth management footprint in the country.
UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates https://seekingalpha.com/news/4079564-ubs-sees-lilly-glp-1sleep-apnea-study-falling-short-of-street-estimates?source=feed_sector_healthcare Mar 14, 2024 - UBS said it believes that upcoming data for Eli Lilly’s (LLY) GLP-1 drug tirzepatide in the treatment of sleep apnea will come in below Street expectations. Read more here.
UBS (UBS) Up 5% Since Last Earnings Report: Can It Continue? https://www.zacks.com/stock/news/2237436/ubs-ubs-up-5-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2237436 Mar 07, 2024 - UBS (UBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
UBS Group AG (UBS) Aided by Strategic Buyouts Amid High Costs https://www.zacks.com/stock/news/2232509/ubs-group-ag-ubs-aided-by-strategic-buyouts-amid-high-costs?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2232509 Feb 27, 2024 - Business restructuring plans and strategic acquisitions support UBS Group AG's (UBS) financials. However, rising costs will likely limit bottom-line growth.
UBS cuts BioXcel to neutral; cites regulatory issues, financing https://seekingalpha.com/news/4069650-ubs-cuts-bioxcel-to-neutral-cites-regulatory-issues-financing?source=feed_sector_healthcare Feb 21, 2024 - UBS has downgraded BioXcel Therapeutics (BTAI) to neutral, citing too much uncertainty about the company’s financing, regulatory alignment with the FDA, and end
Alkermes downgraded at UBS as stock nears 52-week high https://seekingalpha.com/news/4069051-alkermes-downgraded-ubs-stock-nears-52-week-high?source=feed_sector_healthcare Feb 20, 2024 - UBS downgrades Alkermes to sell due to disappointing sales and negative pipeline update. Read more here.
Nvidia: UBS Note Should Raise Alarms https://seekingalpha.com/article/4670524-nvidia-ubs-note-should-raise-alarms?source=feed Feb 15, 2024 - UBS raises Nvidia's (NVDA) earnings estimates and price target, but warns of near-term trouble for growth due to decreased lead times. Learn why it is posing a risk for investors.
UBS starts Axsome at buy, sees Auvelity hitting $1B sales by 2030 https://seekingalpha.com/news/4064942-ubs-starts-axsome-at-buy-sees-auvelity-hitting-1b-sales-by-2030?source=feed_sector_healthcare Feb 08, 2024 - UBS has initiated coverage of Axsome Therapeutics (AXSM) with a buy rating, commenting that it was bullish on the launch of the company’s drug Auvelity and upco
UBS starts Biohaven at buy, cites diverse pipeline https://seekingalpha.com/news/4064106-ubs-starts-biohaven-at-buy-cites-diverse-pipeline?source=feed_sector_healthcare Feb 07, 2024 - UBS has initiated coverage of Biohaven (BHVN) with a buy rating, citing its attractive valuation and diverse pipeline. The investment bank said it was “bullish
UBS Q4 Earnings Decline Y/Y on Higher Expenses, Revenues Up https://www.zacks.com/stock/news/2222803/ubs-q4-earnings-decline-y-y-on-higher-expenses-revenues-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2222803 Feb 07, 2024 - A rise in operating expenses hinders UBS' Q4 earnings. Though the Business divisions' performances have not been so impressive, it managed to report higher revenues.

Pages: 123

Page 1>